|
Q-Cells® Products
Q-Cells® will initially target treatment of transverse myelitis, multiple sclerosis (MS), traumatic spinal cord injuries and amyotrophic lateral sclerosis (ALS, or Lou Gehrig's Disease). Q-Cell® products may also be developed to address other diseases, including cerebral palsy, stroke, traumatic brain injury, Parkinson's Disease and Alzheimer's Disease.
Additionally, Q-Cells® will be used for screening to expedite development of follow-on pharmaceutical products. By incorporating Q Therapeutics' cells in the screening and development process, companies can test their therapeutic candidates in the living cells that generate the entire central nervous system.
Q-Cells® will be manufactured at the University of Utah's Cell Therapy Facility, in accordance with FDA requirements. The product will then be shipped to specialty neurology centers as an off-the-shelf cell therapy.
|
PRODUCTS 
